Clik here to view.
3rd International Symposium on Cancer, microRNAs, and other non-coding RNAs
Very last minute – but if you are near London and don’t have any plans for Wednesday this might be right event for you: The third international symposium on Cancer, microRNAs and other non-coding RNAs...
View ArticleClik here to view.
miREC: Database of miRNAs involved in endometrial cancer
The miREC database (miRNAs involved in Endometrial Cancer) combines published data about miRNAs and genes deregulated in endometrial cancer, as well as target-regulator relationships between these...
View ArticleClik here to view.
Rosetta Genomics and Precision Therapeutics Announce U.S. Commercial Launch...
Medicare-Covered Assay Accurately Identifies Tumor of Origin in Cancer of Unknown Primary PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ:...
View ArticleClik here to view.
Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of...
PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data...
View ArticleOxidants, antioxidants and the current incurability of metastatic cancers
James Watson, co-discoverer of the structure of DNA, says anti-metastatic RNAi is the key to beating cancer. Sending more government cancer monies towards innovative, anti-metastatic drug development...
View ArticleClik here to view.
miRNAs and Bladder Cancer – Study Validating Ability of microRNAs to Predict...
NOTE: hsa-miR-29c* mentioned in the following paper is the retired name for what is now hsa-miR-29c-5p: http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0004673 PHILADELPHIA and REHOVOT,...
View ArticleClik here to view.
Rosetta Genomics Reports Financial Results for the First Six Months of 2013
Demonstrating Increased Demand for the Rosetta Cancer Origin Test PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Sep 10, 2013) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of...
View ArticleClik here to view.
Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to...
Expands the Company’s Patent Portfolio in Oncology Therapeutics PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of...
View ArticleClik here to view.
Marina Biotech and Mirna Therapeutics Amend License Agreement for the...
Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34 BOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based...
View ArticleClik here to view.
starBase update: deciphering Pan-Cancer patterns of miRNAs, lncRNAs, ceRNAs...
StarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs,...
View Article
